Argenx SE, a global biotech company, is facing an investigation by Pomerantz Law Firm on behalf of its investors. Regardless, the firm has been productive, recently signing a
$1.5 billion contract with
Unnatural Products to transition their peptides to 'undruggable' targets. However, the FDA currently ponders regulatory action on Argenx's drug,
Vyvgart Hytrulo, due to reports of severe disease worsening. Despite this, Argenx's stock shows a bullish behavior, jumping
3% due to heavy volumes and positive technical signals. The 'undruggable' targets project isn't the only one advancing;
Argenx is also making progress on the clinical development of ARGX-119 for Congenital Myasthenic Syndromes. Analyst firms
Goldman Sachs and
BofA view
Argenx positively, reiterating their buy ratings, while other reputable banks have expressed bullish sentiments as well. Amidst the volatility, Argenx progresses its pipeline and strengthens its position in immunology, amidst industry validation.
argenx News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Sat, 12 Jul 2025 14:00:00 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -3
